Part 3/8:
Gilead Sciences made waves in the market when it acquired Kite Pharma for nearly $12 billion, excited about the BOTHLIVE potential of CAR-T therapy. However, the reality is far less impressive; Kite's CAR-T sales year-to-date have only reached $183 million. Similarly, Novartis' Kymriah demonstrates underwhelming commercial performance, generating mere $48 million in sales within the same timeframe. Collectively, CAR-T drugs have reported less than $250 million in sales by the third quarter—significantly lower than the expectations that fueled their development.